News

There is so much happening across Glasgow and the West of Scotland and our news portal will allow us to share it with you.

Scientists break new ground in potential leukaemia treatment

University of Glasgow

Scientists at the University of Glasgow have discovered a potential combination therapy for the treatment of chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in the Western world, diagnosed in more than 3500 people in the UK each year.

The research, carried out in collaboration with NHS Greater Glasgow and Clyde (NHSGGC) and published in Clinical Cancer Research, found that the combination of ibrutinib, a targeted treatment already in clinical use, with a new inhibitor called AZD8055, helped promote CLL cell death in a preclinical study.

This study, which used CLL patient samples and a CLL mouse model, found that combination of these two inhibitors activated a protein called FOXO1, which can function as a ‘molecular brake,’ stopping the cells from multiplying and inducing CLL cell death.

Chronic lymphocytic leukaemia (CLL) is a blood cell cancer affecting white blood cells. The disease more commonly affects people over the age of 60.

The disease course can vary from patient to patient, with some patients experiencing a stable low-grade disease that does not require treatment, while others develop resistance to chemotherapy treatments given and are considered “high-risk” patients.

The introduction of ibrutinib into the clinic as a treatment of high-risk CLL patients has enhanced the survival of this difficult to treat subset of CLL patients.

However the CLL cells can adapt to the drugs, developing mutations and therefore becoming resistant to ibrutinib leaving few therapeutic options for patients. Novel combination of treatments offer the potential to reduce the ability of the CLL cell to adapt to the treatment which attacks the cell in two places as opposed to one.

Dr Alison Michie, who led the study, said: "Reducing the ability of CLL cells to survive is key to interrupting disease progression. In our study, we established that by targeting and inhibiting the function of a protein called mTOR which is often deregulated in cancer, we improved the killing of CLL cells.

“Combining mTOR inhibition with a drug called ibrutinib, which is currently being used in the clinic to treat high-risk CLL patients, enhances the activation of FOXO1, a protein that can promote cell death, in a preclinical model.

"Our findings are important because they could demonstrate a potential new therapeutic approach for treating patients with high-risk CLL.”

The paper AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B cell receptor-mediated survival is published in Clinical Cancer Research. The study was funded by the Medical Research Council (MRC) and Bloodwise.

 

Links

University of Glasgow


No Comments...


Add a comment

01 08 08 06 Audio Captcha
Add Comment
 

 

What’s happening

This is a living, breathing website with regular updates on news, blogs and events. It’s the place to come back to again and again if you want to know what’s happening in the science and technology world in Glasgow and the West of Scotland.

Subscribe to keep up to date on our latest news, blog posts and events.

News

   

Glasgow Kelvin College and Indian partners create apprenticeships for people with additional support needs

Glasgow Kelvin College has welcomed a delegation of partners from India and announced plans to devel...

Read more...


IBioIC leads successful bid to boost Scotland’s ‘bio-revolution’

Ambitious plans to boost the economic impact of Scotland’s burgeoning industrial biotechnology sec...

Read more...


Ground-breaking pancreatic cancer trial reaches patient milestone

A ground-breaking pancreatic cancer trial, which aims to match patients with more targeted and effec...

Read more...

Blog

   

Your guide to all the STEM events at Aye Write! 2019

Explore what’s on offer at Glasgow’s book festival this March. ...

Read more...


You might not know it yet, but industrial biotechnology is vital to our future

Roger Kilburn, CEO of the Industrial Biotechnology Innovation Centre, explains how IB is changing th...

Read more...


Equality Through Innovation: The Comedian

Anna Devitt is using the power of comedy to help disadvantaged young people in Scotland. ...

Read more...

Events

   

Aye Write! Glasgow's Book Festival

Aye Write! remains committed to celebrating Scottish and international writers and writing. The 2019...

Read more...


Bhutan in the Footsteps of George Sherriff

A fabulous exhibition of Sherriff's plant expedition trips to Bhutan in the 1930s and 1940s where he...

Read more...


Wildlife Citizen Science

A talk on conservation surveys and bioblitzes. ...

Read more...

previous post next post